



Liquidia Technologies Contact:

Elle Pishny

919-328-4361

elle.pishny@liquidia.com

LIQUIDIA TECHNOLOGIES APPOINTS DR. JONATHAN SMITH AS CHIEF SCIENTIFIC OFFICER

Research Triangle Park, NC – April 15, 2010 – Liquidia Technologies, a privately held biopharmaceutical company developing particle-based vaccines and therapeutics, announced today that Jonathan F. Smith, Ph.D., has joined the company as Chief Scientific Officer.

Dr. Smith is a pioneer in the development of novel vaccines based on RNA viruses and has over twenty five years of experience in virology, infectious diseases, and vaccine development. Prior to joining Liquidia, Dr. Smith was a co-founder and served as Chief Scientific Officer of AlphaVax, a biotechnology company focused on developing vaccines for infectious disease and cancer. At AlphaVax, Dr. Smith was responsible for optimizing vaccine vector technologies, developing clinical and regulatory strategies, and generating vaccine candidates and adjuvants based on vector technologies. His efforts resulted in over 20 issued patents and contributed to the advancement of multiple vaccine candidates into clinical studies.

“We are delighted to welcome Dr. Smith to our management team,” said Neal Fowler, Chief Executive Officer of Liquidia. “Dr. Smith’s expertise in the development of novel technologies will be a great asset to Liquidia as we advance our PRINT technology across all of our clinical platforms.”

Prior to Alphavax, Dr. Smith was a faculty member in the Department of Microbiology at the University of Maryland Medical School (UMAB), and Chief of Viral Biology at the United States Army Medical Research Institute of Infectious Diseases (USAMRIID). At UMAB and USAMRIID he led applied and vaccine-related research on alphaviruses and hemorrhagic fever viruses. Dr. Smith also directed epidemic investigation and assistance teams that helped control alphavirus outbreaks in South America and identify West Nile virus as the cause of the outbreak in New York in 1999.

“Liquidia was founded on breakthrough discoveries in nanoscale engineering, and on the application of those discoveries to new capabilities in therapeutic design,” said Joseph DeSimone, Liquidia founder and professor of chemistry at the University of North Carolina at Chapel Hill. “We are excited about the addition of Dr. Smith to the Liquidia management team as we believe his experience and accomplishments will allow the company to continue to grow from its strong scientific foundation.”

Dr. Smith received his B.A. from Colby College and his Ph.D. in microbiology/virology from the University of Texas at Austin. He conducted post doctoral research at the Institute for Genetics in Cologne, Germany, and has co-authored over 90 publications in leading journals. Furthermore, he has extensive experience in establishing multifunctional collaborations between industry, government, and academic laboratories.



Liquidia Technologies Contact:

Elle Pishny

919-328-4361

elle.pishny@liquidia.com

About Liquidia

Liquidia Technologies is developing precisely engineered particles for improved delivery of biological and small molecule therapeutics within the initial fields of vaccines, nucleic acid delivery and inhaled therapeutics. The ability to control particle design parameters such as size, shape and composition is allowing Liquidia to address critical unmet needs in the prevention and treatment of human disease. The company was founded in 2004 and is located in Research Triangle Park, North Carolina. www.liquidia.com

###